207 related articles for article (PubMed ID: 37820088)
1. Preclinical glioma models in neuro-oncology: enhancing translational research.
Barachini S; Morelli M; Santonocito OS; Mazzanti CM
Curr Opin Oncol; 2023 Nov; 35(6):536-542. PubMed ID: 37820088
[TBL] [Abstract][Full Text] [Related]
2. A therapeutic update on PARP inhibitors: implications in the treatment of glioma.
Lal S; Snape TJ
Drug Discov Today; 2021 Feb; 26(2):532-541. PubMed ID: 33157194
[TBL] [Abstract][Full Text] [Related]
3. Migration/Invasion of Malignant Gliomas and Implications for Therapeutic Treatment.
Liu CA; Chang CY; Hsueh KW; Su HL; Chiou TW; Lin SZ; Harn HJ
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29642503
[TBL] [Abstract][Full Text] [Related]
4. Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers.
Arakaki AKS; Szulzewsky F; Gilbert MR; Gujral TS; Holland EC
Neuro Oncol; 2021 Nov; 23(23 Suppl 5):S4-S15. PubMed ID: 34725698
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutics for brain tumors: current practice and future prospects.
El Demerdash N; Kedda J; Ram N; Brem H; Tyler B
Expert Opin Drug Deliv; 2020 Jan; 17(1):9-21. PubMed ID: 31971041
[No Abstract] [Full Text] [Related]
6. Malignant Intracranial High Grade Glioma and Current Treatment Strategy.
Zhang X; Zhang W; Mao XG; Cao WD; Zhen HN; Hu SJ
Curr Cancer Drug Targets; 2019; 19(2):101-108. PubMed ID: 29848277
[TBL] [Abstract][Full Text] [Related]
7. Towards controlled drug delivery in brain tumors with microbubble-enhanced focused ultrasound.
Schoen S; Kilinc MS; Lee H; Guo Y; Degertekin FL; Woodworth GF; Arvanitis C
Adv Drug Deliv Rev; 2022 Jan; 180():114043. PubMed ID: 34801617
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide: Expanding its role in brain cancer.
Mrugala MM; Adair J; Kiem HP
Drugs Today (Barc); 2010 Nov; 46(11):833-46. PubMed ID: 21225022
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic analysis of in vitro and in vivo brain tumor models.
Schuster JM; Friedman HS; Bigner DD
Neurol Clin; 1991 May; 9(2):375-82. PubMed ID: 1944106
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical tumor models of primary brain tumors: Challenges and opportunities.
Akter F; Simon B; de Boer NL; Redjal N; Wakimoto H; Shah K
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188458. PubMed ID: 33148506
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
12. A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma.
Herrera-Rios D; Li G; Khan D; Tsiampali J; Nickel AC; Aretz P; Hewera M; Suwala AK; Jiang T; Steiger HJ; Kamp MA; Muhammad S; Hänggi D; Maciaczyk J; Zhang W; Kahlert UD
Sci Rep; 2020 Oct; 10(1):16218. PubMed ID: 33004830
[TBL] [Abstract][Full Text] [Related]
13. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas.
Barth RF
J Neurooncol; 1998 Jan; 36(1):91-102. PubMed ID: 9525831
[TBL] [Abstract][Full Text] [Related]
14. Pro- and Antiangiogenic Factors in Gliomas: Implications for Novel Therapeutic Possibilities.
Groblewska M; Mroczko B
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200145
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system.
Adamson DC; Rasheed BA; McLendon RE; Bigner DD
Cancer Biomark; 2010; 9(1-6):193-210. PubMed ID: 22112477
[TBL] [Abstract][Full Text] [Related]
17. A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology.
Vogelbaum MA; Li G; Heimberger AB; Lang FF; Fueyo J; Gomez-Manzano C; Sanai N
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-8. PubMed ID: 35580289
[TBL] [Abstract][Full Text] [Related]
18. Improving outcomes for neurofibromatosis 1-associated brain tumors.
Brossier NM; Gutmann DH
Expert Rev Anticancer Ther; 2015 Apr; 15(4):415-23. PubMed ID: 25652347
[TBL] [Abstract][Full Text] [Related]
19. Central Nervous System: Notable Developments in the Management of Primary and Recurrent Gliomas.
Nabors LB
J Natl Compr Canc Netw; 2016 May; 14(5 Suppl):681-4. PubMed ID: 27226514
[TBL] [Abstract][Full Text] [Related]
20. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
Ziegler J; Pody R; Coutinho de Souza P; Evans B; Saunders D; Smith N; Mallory S; Njoku C; Dong Y; Chen H; Dong J; Lerner M; Mian O; Tummala S; Battiste J; Fung KM; Wren JD; Towner RA
Neuro Oncol; 2017 Feb; 19(2):175-185. PubMed ID: 27416955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
